February 25, 2019 / 11:13 AM / 24 days ago

BRIEF-Roche CEO says $4.3 Bln Spark Deal "Goes Beyond Haemophilia A"

Feb 25 (Reuters) - Roche Holding Ag:

* CEO SAYS HAEMOPHILIA GENE THERAPY IS AN IMPORTANT PART OF SPARK ACQUISITION, BUT THAT DEAL "GOES BEYOND HAEMOPHILIA A" TO REST OF PORTFOLIO

* CEO SAYS FEELS NOW IS THE RIGHT TIME TO "STEP UP" AND EXTEND PORTFOLIO INTO GENE THERAPY

* CEO SAYS SEES HAEMOPHILIA GENE THERAPY, HEMLIBRA ARE COMPLEMENTARY PRODUCTS

* CEO SAYS ROCHE CONVINCED STEROID PROPHYLAXIS SUFFICIENT TO MITIGATE IMMUNE RESPONSE OBSERVED IN HAEMOPHILIA A GENE THERAPY FROM SPARK

* CEO SAYS DOES NOT SEE PRICING BENEFIT TO HAVING BOTH GENE THERAPY, HEMLIBRA FOR HAEMOPHILIA A

* CEO SAYS MUST FIND "SUSTAINABLE REIMBURSEMENT SCHEMES" FOR ONE-TIME GENE THERAPY, INCLUDING THE INTRODUCTION OF ANNUITIES BASED ON EFFICACY

* CEO SAYS SPARK'S HAEMOPHILIA A GENE THERAPY HAS POTENTIAL TO BE "BEST IN CLASS" BASED ON CLINICAL TRIALS, SAYS REST OF PORTFOLIO IS "DIFFERENTIATED"

* CEO SAYS SPARK DEALS WITH NOVARTIS, PFIZER WILL CONTINUE AFTER ROCHE ACQUISITION

* CEO SAYS GENE THERAPY CONTRIBUTIONS TO SALES WILL DEPEND ON SPARK PIPELINE EVOLUTION Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below